Shionogi & Company Limited

Hokkaido University

Naoki Ohyabu

Manabu Katou

Masafumi Iwatsu

Yoshikazu Sasaki

Yuji Nishiura

Kana Kurahashi

Nobuyuki Tanaka

Toshihiro Wada

Shin-Ichiro Nishimura

Yoshito Numata

Eiichi Kojima

Shoichi Naito

Masahiko Fujioka

Yu Hinata

Keisuke Tonogaki

Akira Ino

Keisuke Miyazaki

Tatsuya Takahashi

Naotake Kobayashi

Junji Onoda

Takatsugu Inoue

Yutaka Tomida

Masataka Fumoto

Keiko Kawamoto

Kentarou Asahi

Masahide Ohdan

Tomomi Urabe

Hiroshi Hinou

The present invention relates to a compound represented by Formula (I): wherein X is, for example, C(&#x2550;O); Z is, for example, C(&#x2550;O); L is, for example, a single bond; A is, for example, aromatic carbocycle; R is, for example, Ror B; Ris, for example, hydrogen; Ris, for example, substituted or unsubstituted alkyl; Ris, for example, hydrogen; Ris, for example, hydrogen; Ris, for example, halogen; Ris, for example, halogen; Ris, for example, hydrogen; Ris, for example, hydrogen; Ris, for example, hydrogen; Ris, for example, hydrogen; m is 0 to 5; n is 0 to 5; and p is 1 to 6, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.

Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity

The purpose of the present invention is to provide novel compounds having ACC2 selective inhibitory activity. In addition, the present invention provides a pharmaceutical composition comprising the compound. A compound of Formula:  

9-membered fused ring derivative

The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I): 

Alkylene derivatives

Disclosed is a compound which is useful as an AMPK activator. A compound represented by formula: or a pharmaceutically acceptable salt thereof,

Azabenzimidazole derivative having AMPK-activating activity

Disclosed is a compound which is useful as an AMPK activator. A compound represented by formula: 

An objective of the present invention is to provide a MUC1 antibody having high specificity to cancer cells. The objective has been achieved by the present inventors who found that a cancer-specific sugar chain can be specifically recognized in MUC1 and a cancer cell expressing MUC1 having such a cancer cell specific sugar chain can be recognized. The present invention provides an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, having, for example, 40-fold specificity or more for a cancer-associated structure of MUC1 as compared to that of a normal tissue-associated structure of MUC1.

MUC1 antibody

An object of the present invention is to provide an antibody which does not bind to a normal cell, and is specific for a cancer cell. The object was solved by the finding by the present inventors that an antibody obtained by immunizing an animal using a 2,3ST glycopeptide as an antigen unexpectedly recognizes a sugar chain specific for a cancer specifically and remarkably, and consequently, can recognize and kill a cancer cell expressing MUC1 having such a cancer cell-specific sugar chain. The present invention provides, for example, an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, in which specificity for a cancer-associated structure of MUC1 is 100-fold or more as compared with that for a normal tissue-associated structure of MUC1.

Anti-MUC1 antibody

Growing community of inventors

Osaka, Japan

Naoki Ohyabu